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BACKGROUND: We evaluated the association between polymorphisms of cytochrome P450 2A6 (CYP2A6)/excision repair cross-
complementation group 1 (ERCC1)/X-ray repair cross-complementing group 1(XRCC1) and treatment outcomes of metastatic
gastric cancer (MGC) patients treated with S-1/cisplatin.
METHODS: Among MGC patients (n¼108), who received S-1 (40mgm
 2 b.i.d., days 1–14) and cisplatin (60mgm
 2, day 1) every
3 weeks, we analysed the wild-type allele (W) and variants (V)o fCYP2A6 (*4, *7, *9, *10), and the polymorphisms of ERCC1
(rs11615, rs3212986) and XRCC1 (rs25487).
RESULTS: Patients having fewer CYP2A6 variants had better response rates (W/Wv sW /V other than *1/*4 vs V/V or *1/*4¼66.7 vs
58.3 vs 32.3%; P¼0.008), time to progression (TTP) (7.2 vs 6.1 vs 3.5 months, P¼0.021), and overall survival (23.2 vs 15.4 vs 12.0
months, P¼0.004). ERCC1 19442C4A (rs3212986) was also associated with response rate (C/C, 46.7% vs C/A, 55.3% vs A/A, 87.5%)
(P¼0.048) and TTP (4.4 vs 7.6 vs 7.9 months) (P¼0.012). Patients carrying both risk genotypes of CYP2A6 (V/V or 1/*4) and ERCC1
19442C4A (C/C) vs those carrying none showed an adjusted odds ratio of 0.113 (P¼0.004) for response, and adjusted hazard ratios
of 3.748 (P¼0.0001) for TTP and 2.961 (P¼0.006) for death.
CONCLUSION: Polymorphisms of CYP2A6 and ERCC1 19442C4A correlated with the efficacy of S-1/cisplatin.
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Gastric cancer is the second most common cause of cancer death
worldwide and the most common cancer in Korea (Parkin et al,
2005; Shin et al, 2007). As unresectable or metastatic gastric cancer
(MGC) patients have a dismal prognosis with a median survival of
less than 1 year despite chemotherapy, more effective treatment is
urgently needed.
Until recently, the most common combination chemotherapies
for MGC were based on infusional fluorouracil (5-FU) and/or
cisplatin, with cisplatin/5-FU and epirubicin/cisplatin/5-FU
regarded as reference treatments. Interest in oral fluoropyrimidines
has been increasing, however, because of the convenience and
safety they offer, and a novel oral fluoropyrimidine, S-1 is being
actively investigated. In recent phase III trial, S-1 alone, or
combined with cisplatin, showed promising activity as both a
palliative and as an adjuvant therapy in advanced gastric cancer
(Sakuramoto et al, 2007; Koizumi et al, 2008; Boku et al, 2009;
Ajani et al, 2010). Now that several phase III trials have
demonstrated that both capecitabine and S-1 are not inferior to
5-FU in the setting of a platinum-containing combination, oral
fluoropyrimidine plus platinum combinations are being widely
used in clinical practice or as novel reference regimens in clinical
trials (Cunningham et al, 2008; Kang et al, 2009; Ajani et al, 2010).
In addition, S-1 plus cisplatin shows a better safety profile than
5-FU plus cisplatin (Ajani et al, 2010). On the basis of these
efficacy and safety data, S-1 plus cisplatin has become one of the
most commonly used regimens in MGC, yet little is known about
which subset of patients is most likely to benefit from the therapy.
Identification of predictive markers for efficacy and/or toxicity
could lead to more tailored therapy and, ultimately, improved
treatment outcomes. An oral fluoropyrimidine, S-1, consists of
5-chloro-2,4-dihydroxypyridine, potassium oxonate, and tegafur,
which is converted to 5-FU in the liver mainly by cytochrome P450
2A6 (CYP2A6) (Shirasaka et al, 1996; Ikeda et al, 2000). The
enzyme CYP2A6 has polymorphic variants; CYP2A6*2, *4, *5, and
*20 show no enzyme activity, whereas CYP2A6*6, *7, *9, *10, *11,
*12, *17, *18, and *19 show reduced activity (http://www.cypalleles.
ki.se). Recent pharmacokinetic studies showed the plasma
concentrations and clearances of 5-FU and/or tegafur differed
according to the CYP2A6 polymorphisms in patients treated
with S-1 (Fujita et al, 2008; Kaida et al, 2008; Kim et al, 2009).
Here we hypothesise that CYP2A6 polymorphisms affect the
clinical outcomes of patients who are undergoing S-1-containing
chemotherapy for MGC – poorer efficacy and/or lower toxicity in
patients with defective variant alleles.
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that cause inter- or intrastrand crosslinking. Nucleotide excision
repair (NER) and base excision repair (BER) systems are involved
in the repair of such damage. Key and rate-limiting enzymes
include excision repair cross-complementation group 1 (ERCC1)
in NER and X-ray repair cross-complementing group 1 (XRCC1)
in BER, and they could lead to less cisplatin-induced DNA damage
and thus to a poor drug response (Bosken et al, 2002; Furuta et al,
2002; Reed, 2005; Olaussen et al, 2006). Polymorphisms of those
DNA repair enzymes are associated with altered functional activity
and variations in clinical outcome in patients treated with
cisplatin-based chemotherapy (de las Penas et al, 2006; Krivak
et al, 2008; Bradbury et al, 2009; Kalikaki et al, 2009; Shim et al,
2010). Although there are other important factors in DNA repair
pathways, we selected ERCC1 rs11615 and rs3212986 and XRCC1
rs25487 for genotyping, based on their frequencies of minor alleles
40.1 in Asian populations according to the Single-Nucleotide
Polymorphism database (http://www.ncbi.nlm.nih.gov/projects/
SNP), and previous findings of associations with treatment
outcomes of gastric cancer patients treated with platinum (Liu
et al, 2007; Goekkurt et al, 2009; Huang et al, 2009).
In this study, we investigated association between CYP2A6,
ERCC1, and XRCC1 polymorphisms and clinical outcomes of MGC
patients who received S-1 plus cisplatin chemotherapy.
PATIENTS AND METHODS
Study population and treatment
We prospectively collected clinical data on 134 consecutive MGC
patients who had received palliative S-1 plus cisplatin as first-line
chemotherapy in the Center for Gastric Cancer of the National
Cancer Center, Korea, between April 2006 and April 2010. Of those,
we excluded 10 patients who did not have measurable lesions,
9 who were lost to follow-up during the first cycle, and 7 in whom
blood samples were not available, leaving 108 patients eligible for
analysis. Other eligibility criteria included Eastern Cooperative
Oncology Group (ECOG) performance status p2, age X18 years,
no concurrent uncontrolled medical illness, and adequate haema-
tological (absolute neutrophil count X1500 per ml, platelet count
X100000 per ml), hepatic (aminotransferase p2.5 the upper
limit of normal (ULN)) (p 5   ULN in the presence of liver
metastases), total bilirubin p1.5 ULN), and renal (creatinine
p1.5 ULN) function.
Treatment consisted of 40mgm
 2 oral S-1 twice daily (within
the hour following morning and evening meals) on days 1 to 14,
and a 15-min intravenous infusion of cisplatin 60mgm
 2 on day 1
of a 3-week cycle. Prophylactic administration of granulocyte-
colony stimulating factor was not allowed. To prevent nausea
and vomiting, 5-hydroxytryptamine-3 receptor antagonists and
dexamethasone and/or aprepitant were administered before
chemotherapy. Treatment was continued in the absence of disease
progression or unacceptable toxicity.
All patients provided written informed consent, and the study
was approved by the Institutional Review Board at the Research
Institute and Hospital, National Cancer Center. All information
was obtained with appropriate Institutional Review Board waivers.
Assessment of efficacy and toxicity
Computed tomography scans were performed every 2–3 cycles or
if clinically indicated to evaluate tumour response to treatment,
which was assessed according to Response Evaluation Criteria in
Solid Tumors (Therasse et al, 2000). Objective responses were
confirmed by a second evaluation 4 to 6 weeks later.
The response rate and time to progression (TTP) were assessed
by investigators. A complete blood cell count with differential,
serum chemistry profile, and electrolyte level analysis were
performed every 3 weeks. Toxicity was graded according to
National Cancer Institute Common Toxicity Criteria (version 3.0).
CYP2A6, ERCC1, and XRCC1 genotyping
Using genomic DNA extracted from 3ml peripheral blood with a
Qiagen DNA extraction kit (Qiagen, Hilden, Germany), we
identified the common variant alleles that affect CYP2A6 activity
or expression in Asian populations (CYP2A6*4, *7, *9, and *10), as
well as the wild-type allele (CYP2A6*1), as previously described
(Kong et al, 2009). Briefly, we used polymerase chain reaction
(PCR)–restriction fragment length polymorphism, sequencing,
and primer extension methods to determine three polymorphic
sites (–48T4G, 6558T4C, and 6600G4T) and deletion of the
CYP2A6 gene. We used a GeneAmp PCR system 9700 thermal
cycler (Applied Biosystems, Foster City, CA, USA) and performed
electrophoresis with an ABI Prism 3100 analyser (Applied
Biosystems).
We genotyped ERCC1 polymorphisms, including rs11615
{NG_015839.1}: g.8525C4T p.Asn118Asn) and rs3212986
{NG_015839.1}:g.19442C4A,a t3
0
untranslated region), using the
TaqMan SNP assay (Applied Biosystems) following the man-
ufacturer0s directions. We performed sequence analysis for rs25487
of the XRCC1 polymorphism ({NM_006297.2}:c.1196G4A,
p.Arg399Gln), using the PCR product, which was reacted with
a mixture of HF taq premix (Bioneer, Daejeon, Korea), primers
(F: 5
0
-CCTCTCTCGTTCCCCTTTG-3
0
and R: 5
0
-AGGTCCTCCTTC
CCTCATCT-3
0
), and sample DNA.
Statistical analysis
We assessed associations between variables using the Pearson w
2-
test or the Fisher’s exact test for categorical variables. We
performed multivariate logistic regression analyses to ascertain
whether the genetic polymorphisms are independently associated
with treatment responses after adjusting for other relevant
variables. We defined TTP as the time from the initiation of
treatment to the date of documented disease progression, and
defined overall survival (OS) as the time from the initiation of
treatment to the date of death from any cause or the last follow-up
visit. We used the Kaplan–Meier method and the log-rank test to
estimate and compare survival distribution, and used Cox-
regression models for survival multivariate analysis. We used
trend tests to assess statistical significance of changes in the
relationship between treatment efficacy and genetic polymorph-
ism. We categorised genetic polymorphisms on an ordinal scale,
according to genotypes (0 for homozygous non-risk allele, 1 for
heterozygous risk allele, and 2 for homozygous risk allele), with
risk alleles defined as those associated with poorer treatment
efficacy. We considered the results as statistically significant when
two-sided P-values were o0.05.
RESULTS
Patient characteristics
Table 1 shows the clinical characteristics of the 108 eligible
patients. Their median age was 57 years (range, 26–72), and the
median follow-up period was 19.9 months (range, 1.4–59.1
months). Most (88.9%) of the patients had an ECOG performance
status of 0–1, and all had metastatic disease, with 24 (22.2%) of
them having recurrent metastatic disease after previous curative
gastrectomy. Among the characteristics listed in Table 1, ECOG
performance status (0–1 vs 2) was significantly associated
with tumour response rate (Pearson w
2-test, P¼0.008), TTP
(log-rank Po0.001), and OS (log-rank Po0.001); sex was signi-
ficantly associated with tumour response rate (Pearson w
2-test,
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sP¼0.004) and TTP (log-rank P¼0.041); and number of organs
with metastases (o3 vs X3) was significantly associated with TTP
(P¼0.029).
Genotype frequencies
Table 2 shows the frequencies of the various genotypes. The allelic
frequencies were 0.57 for CYP2A6*1, 0.13 for CYP2A6*4, 0.07 for
CYP2A6*7, 0.20 for CYP2A6*9, and 0.03 for CYP2A6*10, and were
comparable to those previously reported in Asian populations
(Kwon et al, 2001; Schoedel et al, 2004; Mwenifumbo et al, 2005;
Nakajima et al, 2006). To analyse the effect of the CYP2A6
polymorphisms on treatment outcomes, we classified CYP2A6*4,
CYP2A6*7, CYP2A6*9, and CYP2A6*10 as variant alleles. We
assigned patients who carried *1/*7, *1/*9,o r*1/*10 to a wild-type/
variant (W/V) group and those who carried two variant alleles to a
variant/variant (V/V) group. However, because CYP2A6*4 leads to
deletion of the entire gene and thus loss of enzyme activity
(patients homo- or heterozygous for the *4 allele might have lower
enzyme activity or expression than those with other allele
variants), we sorted the genotypes into three groups – W/W,
W/V other than *1/*4, and V/V or *1/*4.
The frequencies were 0.76 and 0.24 for the C and T alleles,
respectively, of rs11615 (Asn118Asn)o fERCC1, 0.75 and 0.25 for
the C and A alleles at 19442C4A of ERCC1 (rs3212986), and 0.63
and 0.37 for the G and A alleles of rs25487 (Arg399Gln)o fXRCC1.
We found no significant association between any polymorphisms
and age, sex, ECOG performance status, disease status, histology,
tumour location, or number of organs with metastases (data not
shown).
Association between genotype and tumour response
Two of the eligible patients were lost to follow-up after the first
chemotherapy cycle, leaving 106 patients, who could be evaluated
for tumour response. Of those, 56 (52.8%) achieved partial
response, 28 (26.4%) had stable disease, and 22 (20.8%) showed
disease progression. The objective tumour response rate was 52.8%
(95% confidence interval (CI), 43.3–62.3). In univariate analysis,
the CYP2A6 genotype was significantly associated with tumour
response rates; 66.7% for W/W patients vs 58.3% for W/V other
than *1/*4 vs 32.3% for V/V or *1/*4 (Pearson w
2-test, P¼0.019;
trend test, P¼0.008) (Table 3). In multivariate logistic regression
analysis, the CYP2A6 genotype was significantly associated with
the tumour response after adjustment for ECOG performance
status and sex. The adjusted odds ratios (ORs) of patients with
W/V other than *1/*4, and those with V/V or *1/*4, relative to
patients with W/W, were 0.771 (95% CI, 0.262–2.268; P¼0.636)
and 0.220 (95% CI, 0.067–0.719; P¼0.012), respectively (Table 4).
ERCC1 19442C4A was also associated with tumour response rate
in univariate analysis (C/C, 46.7% vs C/A, 55.3% vs A/A, 87.5%)
(Fisher’s exact test, P¼0.093; trend test, P¼0.048) (Table 3).
When we investigated the combined effect of CYP2A6 and ERCC1
19442C4A genotypes on response rate by classifying patients into
three groups according to number of risk genotypes (0, 1, or 2) for
V/V or 1/*4, and C/C, we found that the response rate went down,
as the number of risk genotypes went up, and the association was
significant (63.6% (95% CI, 47.2–80.0) for group with 0 risk
Table 2 Genotype frequency
Genotype No. of patients %
CYP2A6
W/W
*1/*1 28 25.9
W/V other than *1/*4
*1/*7 12 11.1
*1/*9 32 29.6
*1/*10 4 3.7
V/V or *1/*4
*1/*4 19 17.6
*4/*7 3 2.8
*4/*9 5 4.6
*4/*10 2 1.9
*9/*9 3 2.8
ERCC1 (rs11615) 8525C4T
C/C 64 59.3
C/T 37 34.3
T/T 7 6.5
ERCC1(rs3212986) 19442C4A
C/C 62 57.4
C/A 38 35.2
A/A 8 7.4
XRCC1 (rs25487) 1196G4A
G/G 49 45.4
G/A 38 35.2
A/A 21 19.4
Abbreviations: V¼variant allele that abolishes or reduces CYP2A6 activity (*4, *7,
*9, and *10); W¼wild-type allele of CYP2A6 (*1).
Table 1 Patient characteristics (n¼108)
Characteristic No. of patients %
Gender
Male 74 68.5
Female 34 31.5
Median age, years (range) 57 (26–72)
ECOG performance status
0 3 2.8
1 93 86.1
2 12 11.1
Tumour histology
W/D or M/D adenocarcinoma 30 27.8
P/D, signet ring cell, or mucinous carcinoma 78 72.2
Tumour location in stomach
Upper one third 17 15.7
Lower two thirds 70 64.8
Whole stomach 21 19.4
Organ with metastases
Peritoneum 67 62.0
Abdominal distant lymph node 37 34.3
Liver 30 27.8
Bone or lung 12 11.1
Others 40 37.0
No. of organs with metastases
1 49 45.4
2 38 35.2
X3 21 19.4
Disease status
Initial metastatic 84 77.8
Recurrent 24 22.2
Prior treatment
Total gastrectomy 13 12.0
Subtotal gastrectomy 27 25.0
Palliative gastrojejunostomy 2 1.9
Adjuvant chemotherapy 12 11.1
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; M/D¼moderately
differentiated; P/D¼poorly differentiated; W/D¼well differentiated.
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16.7% (95% CI, 0–33.9) for group with both) (Pearson w
2-test,
P¼0.003; trend test, P¼0.004) (Table 3). Adjusted ORs for
tumour response for patients carrying one and two risk genotypes,
compared with those carrying none, were 0.814 (95% CI, 0.308–
2.151; P¼0.678) and 0.113 (95% CI, 0.025–0.509; P¼0.004),
respectively (Table 4). Other genotypes showed no association with
response rate (Table 3).
Association between genotypes and TTP and OS
Time to progression varied significantly with CYP2A6 genotype
(median TTP, 7.2 months for W/W patients vs 6.1 months for W/V
other than *1/*4 vs 3.5 months for V/V or *1/*4) (log-rank
P¼0.032; trend test P¼0.021) (Table 3, Figure 1A), and the
CYP2A6 genotype was a significant independent risk factor
for TTP after adjustment for ECOG performance status, sex,
and number of organs with metastases (Table 4). The adjusted
hazard ratios (HRs) of patients with W/V, other than *1/*4,
and those with V/V or *1/*4, relative to patients with W/W
were 1.165 (95% CI, 0.686–1.981; P¼0.572) and 2.288 (95% CI,
1.245–4.207; P¼0.008), respectively (Table 4). Overall survival
also varied significantly with CYP2A6 genotype (median OS,
23.2 months for W/W patients vs 15.4 months for W/V other
than *1/*4 vs 12.0 months for V/V or *1/*4) (log-rank P¼0.016;
trend test P¼0.004) (Table 3, Figure 1B), and the CYP2A6
genotype was a significant independent predictor for OS after
adjustment for ECOG performance status. The adjusted HRs of
patients with W/V other than *1/*4 and those with V/V or *1/*4,
relative to patients with W/W, were 1.806 (95% CI, 0.906–3.598;
P¼0.093) and 3.118 (95% CI, 1.483–6.558; P¼0.003), respectively
(Table 4).
Among the ERCC1 and XRCC1 polymorphisms, ERCC1
19442C4A was significantly associated with TTP, with risk in
the order of C/C4C/A4A/A (median TTP, 4.4 months for C/C
patients vs 7.6 months for C/A vs 7.9 months for A/A) (log-rank
P¼0.041; trend test P¼0.012) (Table 3, Figure 2A). In multi-
variate analysis, the ERCC1 19442C4A genotype was an indepen-
dent predictor for TTP with borderline significance after
adjustment for ECOG performance status, sex, and number of
organs with metastases (adjusted HR for patients carrying C/C
compared with patients carrying A/A genotype as a reference, was
2.365 (95% CI, 0.909–6.155; P¼0.078) (Table 4). The adjusted HR
of patients with A/A or A/C relative to patients with C/C was 1.546
(95% CI, 0.990–2.413; P¼0.055).
The combination of CYP2A6 and ERCC1 19442C4A genotypes
showed the number of risk genotypes had cumulative effects on
TTP (median TTP, 7.6 months (95% CI, 5.979–9.221) for group
with 0 risk genotype; 5.0 months (95% CI, 2.971–7.029) for group
with one; and 3.2 months (95% CI, 2.376–4.024) for group with
both) (log-rank P¼0.0001; trend test, P¼0.0005) (Table 3,
Figure 3A). Adjusted HRs for disease progression for patients
carrying one and two risk genotypes were 1.396 (95% CI, 0.851–
2.290; P¼0.187) and 3.748 (95% CI, 1.900–7.393; P¼0.0001),
respectively (Table 4). Similarly, the number of risk genotypes had
cumulative effects on OS (median OS, 21.2 months (95% CI, 16.1–
26.3) for group with 0 risk genotype; 15.0 months (95% CI, 11.8–
18.2) for group with one; and 7.7 months (95% CI, 0–15.7) for
group with both) (log-rank P¼0.008; trend test, P¼0.007)
(Table 3, Figure 3B). Adjusted HRs for death for patients carrying
one and two risk genotypes were 1.374 (95% CI, 0.750–2.517;
P¼0.303) and 2.961 (95% CI, 1.371–6.393; P¼0.006), respectively
(Table 4).
Association between genotypes and toxicity
The CYP2A6 polymorphisms showed no significant association
with grade 3 or 4 haematological toxicity during the first cycle
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s(leukopenia, P¼1.000; neutropenia, P¼0.784; anaemia, P¼0.353;
thrombocytopenia, P¼0.169). Nor was there an association between
ERCC1 19442C4A genotypes and grade 3 or 4 haematological toxicity
during the first cycle (leukopenia, P¼0.273; neutropenia, P¼0.290;
anaemia, P¼1.000; thrombocytopenia, P¼1.000). The same was
true for ERCC1 8525C4T( leukopenia, P¼1.000; neutropenia,
P¼0.909; anaemia, P¼0.310; thrombocytopenia, P¼0.625), and
for XRCC1 variation (leukopenia, P¼0.672; neutropenia, P¼0.600;
anaemia, P¼0.158; thrombocytopenia, P¼0.590). We also found
no significant association between any genotype and non-
haematological toxicity during the first cycle (data not shown).
DISCUSSION
In this retrospective study of MGC patients given S-1 plus cisplatin
as first-line chemotherapy, we demonstrated that CYP2A6 and
ERCC1 19442C4A polymorphisms correlated with treatment
efficacy, and that CYP2A6 polymorphism was an especially strong
independent predictor for all efficacy endpoints – response rate,
TTP, and OS. Response, TTP, and OS were significantly poorer in
patients with two variant alleles or *1/*4 whose enzyme product
has reduced or no activity and that could result in a reduced
conversion rate of tegafur to 5-FU. Our finding that patients with a
V/V or *1/*4 genotype compared with those with a W/W genotype
had a probability of response of only 0.22 and a 2.29-fold risk of
progression, and a 3.12-fold risk of death are consistent with
finding in MGC patients treated with S-1 plus docetaxel (Kong
et al, 2009). In addition, our present results are supported by the
findings that CYP2A6*4 reduces plasma 5-FU concentration and
increases the area of under the concentration-time curve (AUC)
and Cmax for tegafur in non-small cell lung cancer patients treated
with S-1 alone or in combination with cisplatin (Kaida et al, 2008).
Moreover, in advanced biliary cancer patients, treated with S-1
plus oxaliplatin, the AUC and Cmax for 5-FU and the metabolic
ratio (exposure ratio of 5-FU to tegafur) are significantly higher in
patients homozygous for wild-type CYP2A6 than in those with one
or two variant alleles (*4, *7,o r*9) (Kim et al, 2009), again
suggesting that CYP2A6 genotype is a strong predictor of the
efficacy of S-1-based chemotherapy.
Another predictor that has been suggested is tumour tissue
expression level of mRNA or protein of 5-FU metabolic pathway genes,
such as thymidylate synthase, orotate phosphoribosyltransferase,
Table 4 Multivariate analysis of association between genotype and RR, TTP, and OS
RR TTP OS
Genotype Adjusted OR
a (95% CI) P-value Adjusted HR
b (95% CI) P-value Adjusted HR
c (95% CI) P-value
CYP2A6
W/W 1 (reference) 1 (reference) 1 (reference)
W/V other than *1/*4 0.771 (0.262–2.268) 0.636 1.165 (0.686–1.981) 0.572 1.806 (0.906–3.598) 0.093
V/V or *1/*4 0.220 (0.067–0.719) 0.012 2.288 (1.245–4.207) 0.008 3.118 (1.483–6.558) 0.003
ERCC1 19442C4A
A/A 1 (reference) 1 (reference) 1 (reference)
A/C 0.258 (0.027–2.451) 0.238 1.638 (0.616–4.357) 0.322 1.750 (0.578–5.304) 0.322
C/C 0.192 (0.021–1.748) 0.143 2.365 (0.909–6.155) 0.078 1.988 (0.697–5.670) 0.199
No. of risk genotypes of CYP2A6 and ERCC1 19442C4A
d
0 1 (reference) 1 (reference) 1 (reference)
1 0.814 (0.308–2.151) 0.678 1.396 (0.851–2.290) 0.187 1.374 (0.750–2.517) 0.303
2 0.113 (0.025–0.509) 0.004 3.748 (1.900–7.393) 0.0001 2.961 (1.371–6.393) 0.006
Abbreviations: HR¼Hazards ratio; OR¼odds ratio; OS¼overall survival; RR¼response rate; TTP¼time to progression; V¼variant allele that abolishes or reduces CYP2A6
activity (*4, *7, *9, and *10); W¼wild-type allele of CYP2A6 (*1).
aAdjusted for ECOG performance status (0–1 vs 2) and sex.
bAdjusted for ECOG performance status
(0–1 vs 2), sex, and number of organ with metastases (o3 vs X3).
cAdjusted for ECOG performance status (0–1 vs 2).
dAt-risk genotypes: V/V or 1/*4 for CYP2A6 and C/C for
ERCC1 19442C4A.
Log-rank P = 0.032
Median (months)
W/W 7.2
W/V other than *1/*4 6.1
V/V or *1/*4 3.5
Median (months)
W/W 23.2
W/V other than *1/*4 15.4
V/V or *1/*4 12.0
Log-rank P = 0.016
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Figure 1 Kaplan–Meier curves of (A) time to progression and
(B) overall survival according to CYP2A6 genotype. W¼wild-type allele;
V¼variant allele (CYP2A6*4, *7, *9, or *10).
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sand thymidine phosphorylase (Ichikawa et al, 2006; Choi et al,
2010; Koizumi et al 2010). Results from those studies, however,
have not been consistent. In addition, genotyping peripheral blood
cells, which we did in the present study, is more optimal than
evaluating tumour expression levels of mRNA or protein, in which
there may not be clinical accessibility or the assay may not be
applicable because of arbitrary cutoff levels, lack of standard
criteria, or observer variation.
In the current study, we categorised CYP2A6 polymorphism into
three groups (W/W vs W/V other than *1/*4 vs V/V or *1/*4)
according to the CYP2A6 enzyme activity. As CYP2A6*4 allele and
the other alleles do not have the same enzyme activity – CYP2A6*4
allele causes a CYP2A6 gene deletion, which lacks activity and
CYP2A6*7, *9, and *10 cause the decreased enzymatic activity – we
combined these *7, *9, and *10 defective alleles into a variant allele,
but differentiated *4 from other variant alleles. Previous studies
have shown that the serum nicotine/cotinine ratio (nicotine is
metabolised primarily by CYP2A6 by C-oxidation to cotinine) was
higher in the subjects with CYP2A6*4/*4, *7/*7,o r*9/*9 rather
than in those with CYP2A6*1/*1, and that the inhibitory effects of
CYP2A6*7 on nicotine metabolism were comparable to those by
CYP2A6*9 (Yoshida et al, 2002, 2003). In in vivo measurement of
nicotine oxidation, CYP2A6*4/*7 and CYP2A6*4/*10 demonstrated
similar enzyme activity to CYP2A6*4/*4 (Xu et al, 2002). The
cotinine/nicotine ratios (±s.d.) in the subjects with CYP2A6*9/*9
(4.3±2.4) were significantly lower than those in the subjects with
CYP2A6*1/*9 (7.7±5.6) and CYP2A6*1/*1 (10.4±9.2) (Yoshida
et al, 2003). The subjects with CYP2A6*1/*4 had the lower cotinine/
nicotine ratios (4.79±3.17) than either those with CYP2A6*1/*1
(7.42±6.56), or with CYP2A6*1/*7 (6.27±4.76) (Yoshida et al,
2002). In addition, the mean in vitro coumarin 7-hydroxylase
activities, which are catalysed by CYP2A6, in subjects carrying
CYP2A6*1/*4, CYP2A6*1/*9, and CYP2A6*4/*9 were 41, 71, and
12%, respectively, compared with those of the subjects with
wild-type alleles (Kiyotani et al, 2003). Furthermore, when patients
were classified into three groups (group 1¼wild-type vs group
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Figure 2 Kaplan–Meier curves of (A) time to progression and (B) overall survival according to ERCC1 19442C4A (rs3212986) genotype, (C) time to
progression, (D) overall survival according to ERCC1 8525C4T (rs11615) genotype, (E) time to progression, and (F) overall survival according to XRCC1
1196G4A (rs25487) genotype.
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s2¼CYP2A6*1/*9 or *1/*12 vs group 3¼CYP2A6*1/*2, *1/*4,
*9/*12, *9/*4,o r*9/*9), the fractional clearance of nicotine to
cotinine was about 80% in group 2, and about 50% in group 3
compared with group 1 (Benowitz et al, 2006). The mean total
plasma clearance of nicotine was 18.8±6.0, 15.5±4.9, and
11.7±5.1mlmin
 1kg
 1 in groups 1, 2, and 3, respectively. These
data suggest that CYP2A6*1/*4 results in lower enzyme activity
than other W/V genotypes.
Although ERCC1 19442C4A was significantly associated with
response rate, the exact functional consequences of this poly-
morphism have yet to be elucidated. The 3
0
untranslated region
might affect mRNA stability and result in lower expression levels
of the enzyme (Chen et al, 2000); the lower DNA repair capacity
would increase the damage done by platinum agents and hence,
increase their efficacy. In clinical studies, however, the ERCC1
19442C4A polymorphism has provided variable results. Our
finding that the C/C genotype, compared with the C/A or A/A
genotype, was associated with poorer treatment efficacy is
consistent with studies of cisplatin-treated oesophageal or non-
small cell lung cancer patients (Bradbury et al, 2009; Kalikaki
et al, 2009). In contrast, other studies reported that the A allele
was associated with shorter progression-free survival and/or
OS in stage III non-small cell lung cancer or epithelial ovarian
cancer patients treated with platinum-based chemotherapy
(Zhou et al, 2004; Krivak et al, 2008). These mixed results might
be attributable to variation in patient or tumour characteristics
and treatments delivered across studies.
Our finding that the number of risk genotypes of CYP2A6 and
ERCC1 19442C4A (V/V or *1/*4 and C/C) was significantly
associated with treatment efficacy, and especially, the group with
both showed very poor clinical outcomes (response rate 16.7%,
median TTP 3.2 months, and median OS 7.7 months) suggests that
CYP2A6 polymorphisms predict primarily efficacy of S-1-based
chemotherapy and ERCC1 19442C4A polymorphisms have an
additive predictive role in the S-1 plus cisplatin setting. Further
investigation is warranted to determine whether patients with
CYP2A6 and ERCC1 19442C4A risk genotypes would have better
outcomes if they were treated with fluoropyrimidines that do not
require CYP2A6 activation, such as 5-FU itself or capecitabine,
and/or non-platinum agents.
The present study had the following limitations: (1) Although we
collected clinical data prospectively, this was a retrospective
analysis, so our findings should be validated in prospective studies;
(2) As pharmacokinetic data were not available, we could not
evaluate the association between CYP2A6 genotype and the
pharmacokinetic parameters of S-1 components and their active
metabolites; (3) As the current study is not a prospective,
randomised trial, it cannot be excluded that CYP2A6 gene
polymorphism could be a prognostic factor of gastric cancer
independent of the effect of S-1; (4) We had no functional data for
the ERCC1 19442C4A polymorphisms; (5) We did not analyse
polymorphisms in other genes, such as thymidylate synthase that
might influence 5-FU efficacy.
In conclusion, our study demonstrated that the CYP2A6 and
ERCC1 19442C4A genotypes correlated with the efficacy of S-1
plus cisplatin in MGC patients. These results are consistent with
the findings of our previous study, which reported for the first
time that the CYP2A6 genotype was associated with the treatment
efficacy of S-1 plus docetaxel in MGC patients (Kong et al, 2009).
Large-scale randomised prospective studies are warranted to
validate our findings, which might provide useful information
for selecting appropriate candidates for S-1-based chemotherapy,
ultimately leading to a more tailored approach to chemotherapy.
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Figure 3 Kaplan–Meier curves of (A) time to progression and
(B) overall survival according to the number of risk genotypes of CYP2A6
(V/V or 1/*4) and ERCC1 19442C4A (C/C).
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